VEGFA and retinopathy of prematurity: Because neovascularization in ROP is largely vascular endothelial growth factor (VEGF) driven and anti-VEGF therapy appears to have fewer ocular side effects, various intravitreal anti-VEGF medications have substituted or been in conjunction with traditional laser therapy [6, 7].